The global acutelymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025,
according to a new report by Grand View Research, Inc. Increasing public and
private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising
number of bone marrow biopsies, and availability of other treatment options are
factors expected to increase the adoption of ALL procedures. For instance, The
Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean
Initiative, a collaborative approach between hospitals and healthcare
institutions in Canada, aim to provide free diagnosis and treatment services to
infants suffering from ALL, who meet certain eligibility criteria.
Furthermore,
rising incidence of ALL is anticipated to boost the market. The disease is
prevalent among children below 5 years of age. The risk of contracting ALL is
the highest between the ages of 0 and 20. On the other hand, adults are also at
a risk of developing this condition. The median age of men diagnosed with this
condition is approximately 55 years.
Browse full report by
Grand View Research : http://www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
Further Key Findings From the Report Suggest:
·
Chemotherapy dominated the market in 2016
owing to its high prescription rate, presence of a wide product portfolio, and
easy availability of products
·
Targeted therapy is anticipated to be the
most preferred therapy in comparison to other types of therapies due to its
associated benefits such as target-specific action and its ability to prevent
collateral damage, leading to faster recovery
·
Precursor B-ALL dominated the market in
2016 and is expected to be the fastest growing segment during the forecast
period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are
its subtypes
·
North America dominated the market in 2016
owing to factors such as the increase in demand for chemotherapy regimen such
as CALGB 8811 and oncaspar in this region
·
Asia Pacific is anticipated to be the
fastest growing region with a lucrative CAGR during the forecast period due to
growing awareness about ALL. Furthermore, the rising disposable income and
presence of large population base are some of the factors expected to propel
the growth in this region
·
Key players in this industry are Erytech
Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme
Corporation
·
Key players are focusing on strategies such
as expansion of product portfolio and collaborations. For instance, in June
2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use
Next-Generation Sequencing (NGS) technology to develop gene expression profiles
for immune-oncology therapies
Browse more reports of this category by
Grand View Research: https://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the
global acute Lymphocytic/Lymphoblastic leukemia therapeutics market on the
basis of therapy, type, and region:
Therapy
Outlook (Revenue, USD Million; 2014 - 2025)
·
Chemotherapy
o
Hyper-CVAD
o
CALGB 8811 regimen
o
Linker regimen
o
Nucleoside Metabolic Inhibitors
o
Oncaspar
·
Targeted therapy
·
Radiation Therapy
·
Stem cell transplantation
Type Outlook
(Revenue, USD Million; 2014 - 2025)
·
Philadelphia chromosome
·
Precursor B-cell ALL
·
T-cell ALL
Regional
Outlook (Revenue, USD Million; 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
o
France
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
Middle East & Africa
o
South Africa
View press release of this research
report by Grand View Research:
https://www.grandviewresearch.com/press-release/global-acute-lymphocytic-lymphoblastic-leukemia-therapeutics-marketAbout Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
